表紙
市場調査レポート

PharmaPoint:季節性インフルエンザワクチン - 米国における医薬品の予測と市場分析

PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis

発行 GlobalData 商品コード 258659
出版日 ページ情報 英文 112 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
PharmaPoint:季節性インフルエンザワクチン - 米国における医薬品の予測と市場分析 PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis
出版日: 2012年11月30日 ページ情報: 英文 112 Pages
概要

2012年における米国のインフルエンザワクチン市場は、およそ10億5,000万米ドルとなりました。インフルエンザに対するワクチンの有効性の認識が高まることや、高齢者人口の増加などが、今後の市場成長因子になるでしょう。

当レポートでは、米国の季節性インフルエンザワクチン市場について調査し、市場の概要、競合情勢、主要薬剤の詳細情報とSWOT分析、主要薬剤の売上予測、主要イベントの影響分析、市場影響因子の分析などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状
  • 予後

第4章 疾病管理

  • インフルエンザ予防接種政策
  • 米国
    • ンフルエンザ予防接種の推奨・政策
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合評価
  • 製品プロファイル:主要ブランド

第6章 機会・アンメットニーズ

  • 概要
  • アンメットニーズ
    • 高い患者認識の水準
    • 高齢者・子供(2歳以下)における効能の向上
    • 改善したワクチン副作用のプロファイル
    • より効率的なワクチン製造プロセス
    • よりコスト効果的なワクチン
  • ギャップ分析
  • 機会
    • ウィルス株に対する防御幅の拡大
    • 防御持続期間の増加
    • T細胞の関与

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望薬剤

第8章 市場展望

  • 米国
    • 予測
    • 主なイベント
    • 促進因子・阻害因子

第9章 付録

図表

目次
Product Code: GDHC1011CFR

Summary

GlobalData has released its new Country report, "PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis". Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

The US influenza vaccine market is valued at approximately $1.05 billion in 2012. The projected drivers for market growth include increased patient awareness on the importance of being vaccinated against influenza, the introduction of vaccines with a quadrivalent formulation, a growing elderly population, and introduction of vaccines with improved efficacy in elderly patients.

Sanofi is the current market leader. It was among the first influenza vaccines available in the US, and it has produced a diverse portfolio of influenza vaccines under Sanofi's Fluzone brand. This brand includes trivalent vaccines with novel routes of administration (Fluzone ID) and vaccines with enhanced immunogenicity in elderly recipients (Fluzone High-Dose).

Scope

  • Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2012 to 2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US seasonal influenza market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012 to 2022 in the US.

Table of contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis

4. Disease Management

  • 4.1. Influenza Vaccination Policy
  • 4.2. US
    • 4.2.1. Influenza Vaccination Recommendations and Policies
    • 4.2.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Fluzone
    • 5.3.2. Fluarix/FluLaval
    • 5.3.3. Fluvirin
    • 5.3.4. FluMist
    • 5.3.5. Afluria
    • 5.3.6. Fluad
    • 5.3.7. Fluzone High-Dose
    • 5.3.8. Fluzone ID (Intradermal)
    • 5.3.9. Optaflu

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Higher level of patient awareness
    • 6.2.2. Increased efficacy in the elderly and young children (<2 years old)
    • 6.2.3. Improved vaccine side-effect profiles
    • 6.2.4. More efficient vaccine manufacturing process
    • 6.2.5. More cost-effective vaccines
  • 6.3. Gap Analysis
  • 6.4. Opportunities
    • 6.4.1. Expanded breadth of protection against viral strains
    • 6.4.2. Increased duration of protection
    • 6.4.3. T-cell involvement

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising vaccines in Clinical Development
    • 7.2.1. FluBlok
    • 7.2.2. Influenza VLP Vaccine

8. Market Outlook

  • 8.1. United States
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Vaccine Coverage
    • 9.4.2. Vaccines Included
    • 9.4.3. Key Launch Dates
    • 9.4.4. Influenza Vaccine Tender System Assumptions
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Vaccine Assumptions
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Authors
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Contact Us
  • 9.10. Disclaimer

List of Tables

  • Table 1: Notable Influenza Pandemics
  • Table 2: Symptoms of Influenza
  • Table 3: Influenza Vaccination Recommendation Committees by Country
  • Table 4: Leading Influenza Vaccines, 2012
  • Table 5: Product Profile - Fluzone
  • Table 6: Fluzone SWOT Analysis, 2012
  • Table 7: Product Profile - Fluarix
  • Table 8: Fluarix SWOT Analysis, 2012
  • Table 9: Product Profile - Fluvirin
  • Table 10: Immunogenicity of Agrippal and Fluvirin
  • Table 11: Fluvirin SWOT Analysis, 2012
  • Table 12: Product Profile - FluMist
  • Table 13: FluMist SWOT Analysis, 2012
  • Table 14: Product Profile - Afluria
  • Table 15: Afluria SWOT Analysis, 2012
  • Table 16: Product Profile - Fluad
  • Table 17: Fluad SWOT Analysis, 2012
  • Table 18: Product Profile - Fluzone High-Dose
  • Table 19: Non-inferiority comparison of Fluzone High-Dose and Standard-Dose Vaccines
  • Table 20: Fluzone High-Dose SWOT Analysis, 2012
  • Table 21: Product Profile - Fluzone ID
  • Table 22: Non-inferiority Comparison of Fluzone ID and IM Vaccines
  • Table 23: Fluzone ID SWOT Analysis, 2012
  • Table 24: Product Profile - Optaflu
  • Table 25: Optaflu SWOT Analysis, 2012
  • Table 26: Overall Unmet Needs - Current Level of Attainment
  • Table 27: Clinical Unmet Needs - Gap Analysis, 2012
  • Table 28: Seasonal Influenza Vaccines - Phase Pipeline, 2012
  • Table 29: Product Profile - FluBlok
  • Table 30: FluBlok SWOT Analysis, 2012
  • Table 31: Product Profile - Influenza VLP Vaccine
  • Table 32: Influenza VLP Vaccine SWOT Analysis, 2012
  • Table 33: Sales Forecasts ($m) for Influenza Vaccines in the United States, 2012-2022
  • Table 34: Key Events Impacting Sales of Influenza Vaccines in US, 2012
  • Table 35: Influenza Vaccine Market - Drivers and Barriers, 2012
  • Table 36: Key Launch Dates
  • Table 37: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Influenza Virus Structure
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Seasonal Influenza, 2012-2022
  • Figure 3: Sales for Influenza Vaccines in the United States by Route of Administration, 2012-2022
Back to Top